FDA Warns Baxter Over GMP Issues at Injectable Drug Plant

FDA has issued a warning letter to Baxter International citing significant GMP deficiencies at its Round Lake, IL, manufacturing facility, including recurring cross-contamination involving cephalosporin antibiotics, inadequate sterile manufacturing controls, particulate contamination and failures to properly investigate sterility test results.

The just-posted 9/29 Warning Letter, which followed a March inspection, cited the firm’s environmental monitoring conducted since 1/2025 that repeatedly detected cephalosporin contamination in areas used to manufacture other injectable drugs, despite physical barriers and dedicated ventilation systems intended to separate production operations.

“While your monitoring program detected recurring cross-contamination, it was inadequate to promptly detect loss of containment and cephalosporin contamination in your facility,” the agency letter said. For example, it found that

• Environmental monitoring/sampling was insufficient in both number and location.
• Swab sampling qualification was inadequate to assure low-level recovery.
• Samples were evaluated beyond established solution stability time allowances.

“These inadequacies create risk for underrepresentation of true contamination hazards throughout your facility, create potential for false negative results, and inhibit meaningful data collection upon which your quality unit (QU) can make sound risk-based decisions,” the letter said.

FDA also identified extensive deficiencies with Baxter's aseptic manufacturing operations, including inadequate validation of processes intended to control microbial contamination, insufficient environmental monitoring and airflow turbulence in critical production areas.

Investigators cited recurring positive biological indicator results during equipment requalification studies that Baxter nevertheless considered acceptable. FDA said the findings demonstrated inadequate process effectiveness and warranted further investigation.

The Warning Letter also criticized Baxter's visual inspection procedures for injectable drugs, finding that personnel were not adequately qualified to detect smaller visible particles and that inspection speeds were excessive.

The agency also identified increasing rates of leaking injectable drug containers, raising concerns about the ability of packaging systems to maintain sterility. “Your investigations into the ‘systemic nature’ of container-closure integrity failures lacked effective CAPA to address the significantly increased rate of leak defects in your injectable drug products,” the letter said. “You did not implement sufficient CAPA to ensure remediation of your final inspection program. Further, since 2023, media fill units were found leaking during incubation and you have received numerous leak complaints for marketed products.”

Additionally, the FDA letter raised concerns about a regulatory meeting Baxter and the agency held in 2025 that “discussed similar CGMP violations at this facility. You proposed specific remediations for these violations in your response. FDA also cited similar CGMP violations at other facilities in your company’s network. These repeated failures at multiple sites demonstrate that management oversight and control over the manufacture of drugs is inadequate.”

Based on the nature of the GMP violations identified, FDA recommended that a qualified consultant be retained to evaluate the company’s operations and to assist it in meeting CGMP requirements. “The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA,” the agency said.

Baxter was directed to respond within 15 business days of receiving the Warning Letter.